Moore Capital Management’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

Moore Capital Management’s Portfolio CNST Stock Details CNST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-79,975	Closed	-$1.87M	–	1049
2021 Q1	$1.87M	Sell	79,975 -6,582	-8%	-$199K	0.02%	467
2020 Q4	$2.49M	Sell	86,557 -148,184	-63%	-$3.73M	0.03%	334
2020 Q3	$4.76M	Buy	234,741 +188,741	+410%	+$4.61M	0.09%	202
2020 Q2	$1.38M	Buy	46,000 +16,000	+53%	+$576K	0.04%	201
2020 Q1	$943K	Buy	30,000 +5,000	+20%	+$174K	0.04%	130
2019 Q4	$1.18M	Buy	+25,000	New	+$722K	0.04%	202

Other funds holding CNST

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return

OPU

Omni Partners US Irvine, California $1.95B AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

PIM

Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Moore Capital Management's CNST Position: Q2 2021 in Review

Moore Capital Management sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q2 2021, closing a stake of 79,975 shares — an estimated $1.87M sold.

Moore Capital Management first reported a position in CNST in Q4 2019 and held it in 6 quarters. The position peaked at $4.76M in Q3 2020. 153 funds tracked by Wall St. Rank hold CNST as of Q2 2021.

Moore Capital Management reported no remaining Constellation Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
Moore Capital Management sold 79,975 Constellation Pharmaceuticals, Inc. shares in Q2 2021, an estimated $1.87M.
Moore Capital Management first reported a position in Constellation Pharmaceuticals, Inc. in Q4 2019 and held it in 6 quarters.
Moore Capital Management's Constellation Pharmaceuticals, Inc. position peaked at $4.76M in Q3 2020.
153 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q2 2021.

Based on Moore Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.